Abstract Search

ea0026p30 | Adrenal cortex | ECE2011

Is plasma mitotane level >30 mg/l a serious adverse event in patients with adrenocortical carcinoma (ACC)?: a retrospective analysis of the French COMETE network

Mauclere-Denost S M D , Tabarin A T , Drui D D , Chaillous L C , Salenave S S , Leboulleux S L , Chabre O C , Do-Cao C D C , Dubourg H D , Cuvelier M L C , Young J Y , Baudin E B

Background: Mitotane antitumor efficacy is related to plasma levels. Objective responses have been associated with mitotane plasma levels >14 mg/l. However, high plasma levels >20 or >30 mg/l are at higher risk of toxicity, especially neurotoxicity. National-based survey is lacking to evaluate the frequency and severity of high mitotane plasma levels. Our aim was to retrospectively describe serious adverse events (SAE).Methods: Mitotane plasm...

0 shares

ea0029p1786 | Thyroid cancer | ICEECE2012

Is thyroid cancer recurrence risk increased after transplantation?

Tisset H. , Kamar N. , Faugeron I. , Pouteil-Noble C. , Klein M. , Frimat L. , Mourad G. , Drui D. , Do Cao C. , Vanthygem M. , Noel C. , Leenhardt L. , Rodien P. , Bonichon F. , Morelon E. , Leboulleux S. , Bournaud C. , Kelly A. , Niccoli P. , Schlumberger M. , Borson-Chazot F.

Context: An increased mortality by cancer is reported in grafted patients.Objective: This multicentric study aimed to investigate whether the prognosis of thyroid cancer was modified by transplantationResults: Sixty nine patients (35 M/34 F; median age 41 years) with a history of both thyroid cancer and transplantation were recruited via specialized networks (TUTHYREF and DIVAT). Evolution and outcome were retrospectively analyzed ...

0 shares

ea0026p70 | Endocrine tumours and neoplasia | ECE2011

First prognostic analysis of stage III adrenocartical carcinoma patients after complete resection: a retrospective French Multicentric Study from the INCA-COMETE network

Do Cao C , Leboulleux S , Borget I , Bertherat J , De la Fouchardiere C , Hecart A C , Caron P , Tabarin A , Niccoli P , Rohmer V , Drui D , Schillo F , Raingeard I , Young J , Ghuzlan A , Borson-Chazot F , Bertagna X , Pattou F , Wemeau J L , Francis Z , Libe R , Aubert S , Baudin E

Objective: To assess outcome of stage IIIENSAT adrenocortical carcinoma (ACC) patients after complete macroscopic resection and prognostic factors for disease-free survival (DFS) and overall survival (OS).Methods: A retrospective review of 68 stage III ACC patients treated surgically between 1994 and 2009 in the French COMETE network was performed. Characteristics of patients were reviewed by a single investigator as well as the Weiss score by expe...

0 shares

Endocrine Abstracts

Is plasma mitotane level >30 mg/l a serious adverse event in patients with adrenocortical carcinoma (ACC)?: a retrospective analysis of the French COMETE network

Is thyroid cancer recurrence risk increased after transplantation?

First prognostic analysis of stage III adrenocartical carcinoma patients after complete resection: a retrospective French Multicentric Study from the INCA-COMETE network

BiosciAbstracts